The UC Davis pathogen inhibitor had been developed by a graduate student named Dr. Yuki Tanaka, and Dr. Tanaka was twenty-nine years old and had been in her lab for seventy-two hours straight when Linda brought Kevin to meet her on a Friday afternoon, and she had the particular quality of a person who'd been awake for three days working on the most important problem of her career while also being aware that it was the most important problem of anyone's career.
"Caffeine-based," she said, pulling up her notes. "The pathogen requires a specific adenosine receptor pathway to complete its cellular integration cycle. Caffeine blocks adenosine receptors — that's why it keeps you awake, by blocking the receptors that tell you you're tired. As a side effect, it also blocks one of the LZR-7 pathogen's preferred integration routes." She said this with the flat, slightly too-fast delivery of a person who'd explained a complicated thing many times and had found the shortest path through it. "In exposed individuals, a caffeine-based compound administered within twelve hours of aerosol exposure will slow the integration cycle by approximately sixty to seventy percent."
"Slow," Kevin said. "Not stop."
"Slow. Not stop. The pathogen still integrates eventually. But 'eventually' goes from forty-eight hours to approximately six to eight days. That's a window." She looked at him. "A window for quarantine identification, for medical intervention, for moving people out of hot zones. Six to eight days is the difference between an uncontrolled secondary spread and a manageable one."
Kevin looked at Linda, who had the expression of a person who'd been watching a graduate student work for three days and who was very carefully managing the gap between hope and fact.
"What does 'caffeine-based compound' mean in practical terms?" Kevin asked. "Are we talking about a pharmaceutical? A delivery mechanism? Something that requires production infrastructure?"
"That's where it gets complicated." Dr. Tanaka pulled out a second notebook. "The compound is based on a modified theophylline derivative. Theophylline is related to caffeine — it's used in asthma treatment, been around since the sixties, widely produced. The modification I developed targets the specific LZR receptor pathway." She paused. "Theophylline is available in generic form. The modification requires a synthesis step that can be done with standard pharmaceutical lab equipment."
"So it can be produced."
"It can be produced if you have a pharmaceutical lab willing to do the synthesis on short notice and the regulatory flexibility to administer an unapproved compound to a large population." She looked at him steadily. "Both of those things are complicated."
"The Governor has activated state emergency resources," Kevin said. "Sacramento County Public Health has federal support as of this morning." He pulled out his phone. "If I can get you in front of the county health officer — Dr. Tran — and the state's emergency health coordinator by tomorrow morning, can you make the case?"
Dr. Tanaka looked at her notes. At the three days of work stacked on her desk, the notebooks, the printed models, the equations that were either going to save a lot of people or exist as the most important failed contribution in the history of a city that had come close to not needing future contributions.
"I can make the case," she said.
---
The meeting with Dr. Tran happened Saturday morning at 7 AM in a Sacramento County Public Health conference room with institutional carpet and a whiteboard still bearing the previous meeting's notes about flu vaccine distribution logistics. Dr. Tran had called Kevin a liar four days ago in a press conference that had been on every Sacramento news outlet. He was now the county health officer who had been briefed by the FBI on what had actually been happening at Mather Field, and he was sitting in his own conference room with the expression of a man who was very thoroughly not enjoying the accumulation of contexts.
Kevin respected this. Being publicly wrong about a bioweapon threat had to have a specific feeling, and it was not a feeling that got better with time.
"Dr. Tanaka," Kevin said, "if you'd—"
Dr. Tanaka launched into the explanation before he finished the sentence. She had rehearsed this. She had the notes. She had the compound diagram. She had the receptor pathway models. She had the theophylline comparison and the synthesis protocol and the dosage estimates for the Sacramento metro population based on census data she'd pulled at 3 AM when she couldn't sleep.
Dr. Tran listened. He asked questions. His questions were good — the questions of a doctor, not a bureaucrat, the kind of questions that probed the mechanism rather than the procedure.
When Dr. Tanaka finished, Tran sat back.
"The synthesis timeline," he said.
"Seventy-two hours minimum from the start of production to a usable supply," Dr. Tanaka said. "With three pharmaceutical production facilities running in parallel, possibly forty-eight hours."
"The wild spread reaches the Sacramento metro in nine days." Tran looked at Kevin. "You said nine days."
"Marcus's calculation. Based on the current spread rate and the modeling from the BioVance files." Kevin paused. "Nine days is the outer estimate. It could be faster. The spread rate is not constant — it accelerates in higher population densities."
"If we start production today — assuming we can get the facilities online today — we'd have product in forty-eight to seventy-two hours. Call it three days. That gives us six days of deployment window before the spread arrives." Tran tapped the whiteboard. "The deployment mechanism. Oral administration?"
"Oral, ideally. Water supply additive as a delivery mechanism for broad coverage." Dr. Tanaka was already writing on the whiteboard. "The compound is water-soluble. Adding it to the municipal water supply at the right concentration would provide passive prophylactic coverage to the entire city's water-using population."
Tran was quiet for a moment. "Adding an unapproved compound to the municipal water supply."
"Under a state emergency health declaration, the county health officer has the authority to authorize emergency pharmaceutical interventions including water supply additives," Dr. Tanaka said. "Under California Health and Safety Code section—" She had the code section memorized. She recited it.
Tran looked at Kevin. "You've been in three different impossible situations in the past week and you've come out of all of them."
"Three and a half," Kevin said.
"This is the one that worries me." Tran stood. He went to the window. He looked at Sacramento on a Saturday morning — the farmers market crowd, the joggers, the city going about the weekend business of being a city. "If the compound doesn't work as projected—"
"Six to eight days instead of forty-eight hours," Kevin said. "If it doesn't work, we have a smaller window but we haven't made the situation worse. If we don't try it, we have a two-day window regardless." He looked at Tran's back. "I know you called us liars four days ago. I know that's relevant to this conversation. But the documents we turned over to the FBI this morning change the scale of what you're deciding about."
Tran turned from the window. He looked at Dr. Tanaka.
"Get me the synthesis protocol and the dosage specifications," he said. "I'll have the three-facility conversation by noon. And I want the state emergency health coordinator on the call." He looked at Kevin. "If this works—"
"It'll work," Kevin said.
---
It mostly worked.
The synthesis ran at two facilities, not three — the third facility declined on legal grounds, citing the unapproved compound status and a corporate risk assessment that had not been updated to account for a nine-day bioweapon timeline — and the first delivery of the theophylline derivative reached the Sacramento municipal water system forty-seven hours after Dr. Tran made the call.
The compound worked at roughly fifty-five percent of the projected efficacy.
Not sixty to seventy percent. Fifty-five.
Kevin got this information from Dr. Tanaka on a Monday morning, sitting in the church Sunday school room with the children's Sermon on the Mount still on the corkboard, and Dr. Tanaka delivered it with the face of a person who'd been told that her three days of work was producing results that were quantifiably below the results she'd calculated.
"Fifty-five instead of sixty-five," she said. "The synthesis process introduces a degradation variable. The compound partially degrades in water at the storage temperature. I hadn't modeled the water temperature at Sacramento's distribution system — it's warmer than a controlled lab environment."
"What does fifty-five percent mean in practical terms?"
"The window is four to five days instead of six to eight." She looked at her hands. "For individuals with direct aerosol exposure — not water supply prophylaxis, but the actual wild spread — the inhibitor reduces their acute conversion window from forty-eight hours to approximately three days."
"Three days instead of forty-eight hours," Kevin said. "That's still a window."
"It's still a window. It's a smaller window. The quarantine identification process needs to work faster, the isolation protocols need more resources, the medical infrastructure needs to be set up to handle a faster throughput." She looked up. "Dr. Tran's team can do it. But the margin got tighter."
Kevin thought about margins. He'd been thinking about margins for three weeks. The bioweapon's vent seals had held for two minutes. The conference center evidence had been retrieved with six hours to spare. The FBI had gotten the Facility Gamma coordinates before the window closed.
Fifty-five percent was a margin.
"The other thing," Dr. Tanaka said. She paused. The pause of someone with a second piece of information that had been waiting for the right moment. "The compound has a secondary effect I didn't predict. In already-infected individuals — people in the active conversion phase — the inhibitor doesn't slow the conversion. But it affects the behavior."
Kevin looked at her. "Affects it how?"
"The territorial aggression. The pack organization. The active predator behavior." She had a new notebook open. "I ran a test. The infected individual on the building's fifteenth floor — the one the county containment team is managing as part of the BioVance building assessment — was exposed to the compound through the building's water supply, which is still running. Over seventy-two hours, her territorial behavior decreased significantly."
"You tested it on the infected in the conference center?"
"The county contamination team has been assessing the building all week. They authorized a controlled exposure. The individual showed reduced aggression, reduced territorial assertion, increased... " Dr. Tanaka looked for the right word. "Stillness. She's still infected. The conversion hasn't reversed. But the behavioral component — the aggression, the predatory behavior — it's damped."
Kevin was quiet.
"This means," he said carefully, "that the compound doesn't just extend the window for exposed people. It potentially makes already-infected individuals less dangerous."
"Less dangerous," Dr. Tanaka confirmed. "Not harmless. Not cured. Less dangerous."
Kevin thought about seventy-three infected BioVance employees in a building that was now being assessed by a county containment team. He thought about the pack on the eighth floor, the lobby cluster, the patrol circuits.
He thought about the things he hadn't been letting himself think about in three weeks of not having enough time to think.
"People who used to have names," he said.
"Yes," Dr. Tanaka said.
The room was quiet. The Sunday school crayon drawings on the corkboard. Moses parting the Red Sea, the happy stick-figure Israelites, the cheerful impossible waves.
"Will Dr. Tran know about this?" Kevin asked.
"I'm briefing him this afternoon."
"Tell him I'll be there." Kevin stood. The knee moved with him. "And Dr. Tanaka — the degradation variable. Is it fixable?"
"In a second synthesis run, with adjusted stabilization. Two weeks."
"Two weeks."
"Yes."
Kevin looked at the corkboard. At the water stain on the ceiling. At the Sunday school classroom that had become, in the span of a week, the operational hub of the most important thing he'd ever done, which was also the most terrible and the most necessary and the most uncertain thing he'd ever done.
"Two weeks," he said. "Start the second run today."
Dr. Tanaka was already picking up her phone.
